Immunic, Inc.
IMUX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001280776
No open-market purchases or sales by Immunic, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $130.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 16, 2026
- $114.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −21 vs. previous quarter
- 56
- 13F valueReported value at the end of Q2 2026
- $130.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$97.2M
- No comparable prior period
- Free cash flow, FY2025
- -$86.0M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.95M
- Shares sold short
- Change
- +88.5K
- +4.8% vs. previous
- Days to cover
- 5.73
- At average daily volume
Superinvestors holding IMUX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding IMUX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Immunic, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 20, 2025 (view filing) | Jun 5 | 15 days | Tardio JasonPresident and COO | PPurchase | +12.5K | $0.79 | +$9.88K | New position12.5K after | Amended |
| Jun 20, 2025 (view filing) | Jun 4 | 16 days | Vitt DanielCEO and Director | PPurchase | +15.0K | $0.77 | +$11.6K | +107.1%29.0K after | Amended |
| Jun 16, 2025 (view filing) | Jun 13 | 3 days | Nash DuaneExecutive Chairman | PPurchase | +20.0K | $0.83 | +$16.6K | +124.8%36.0K after | |
| Jun 5, 2025 (view filing) | Jun 4-5 | 1 day | Neermann JoergDirector | PPurchase | +100.0K | $0.767 | +$76.7K | +100.0%200.0K after | 2 lots |
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Whaley GlennChief Financial Officer | PPurchase | +45.0K | $0.71 | +$31.9K | +89.1%95.5K after | |
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Rudick Richard AlanDirector | PPurchase | +143.1K | $0.70 | +$100.2K | +163.9%230.4K after | |
| Nov 13, 2024 (view filing) | Nov 12 | 1 day | Rudick Richard AlanDirector | PPurchase | +87.3K | $1.15 | +$100.4K | New position87.3K after | |
| Feb 28, 2024 (view filing) | Feb 26 | 2 days | Vitt DanielPresident and CEO | PPurchase | +14.0K | $1.31 | +$18.3K | +3.7%390.9K after | |
| May 16, 2023 (view filing) | May 15 | 1 day | Whaley GlennChief Financial Officer | PPurchase | +5.00K | $1.75 | +$8.75K | +24.4%25.5K after | |
| Dec 15, 2022 (view filing) | Dec 13-14 | 2 days | Neermann JoergDirector | PPurchase | +82.0K | $1.26 | +$103.0K | +455.6%100.0K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 56 holdersThe largest institutional positions in Immunic, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Standard Life Aberdeen plc | 824,393 | $12.7M | 0.02% | 00.0% | UnchangedConverted for a 1-for-10 split |
| BVF Inc | 765,295 | $11.8M | 0.30% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Millennium Management LLC | 740,347 | $11.4M | 0.01% | +362,355+95.9% | AddedConverted for a 1-for-10 split |
| Avidity Partners Management LP | 669,941 | $10.3M | 1.65% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Braidwell LP | 645,010 | $9.91M | 0.37% | +645,010 | New |
| Laurion Capital Management LP | 610,326 | $9.38M | 0.68% | +222,110+57.2% | AddedConverted for a 1-for-10 split |
| Vanguard Capital Management LLC | 571,561 | $8.78M | 0.00% | +57,729+11.2% | AddedConverted for a 1-for-10 split |
| Jones Hill Capital LP | 539,814 | $8.30M | 1.76% | +539,814 | New |
| Woodline Partners LP | 471,528 | $7.25M | 0.02% | +374,813+387.5% | AddedConverted for a 1-for-10 split |
| Soleus Capital Management, L.P. | 450,000 | $6.92M | 0.24% | 00.0% | UnchangedConverted for a 1-for-10 split |
Holders of 5% or more of IMUX
See all 16 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Immunic, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 13G | 9.99%29.1M shares | New | Feb 20, 20261 filing | Feb 20, 2026 | SEC |
| Biotechnology Value Fund L P | 13D | 9.99%13.6M shares | 0.00 ppfrom 9.99% | Jan 18, 20243 filings | Feb 20, 2026 | SEC |
| Janus Henderson Group PLC | 13G | 9.99%12.0M shares | +6.99 ppfrom 3.00% | Jan 18, 20244 filings | Dec 8, 2025 | SEC |
| Adage Capital Management, L.P. | 13G/A | 9.99%10.5M shares | +8.44 ppfrom 1.55% | Nov 12, 20243 filings | Aug 12, 2025 | SEC |
| Avidity Partners Management LP | 13G | 9.90%14.0M shares | +5.10 ppfrom 4.80% | Jan 16, 20247 filings | Apr 17, 2026 | SEC |